2023
A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma
Chen Y, Lin X, Zou X, Qian Y, Liu Y, Wang R, Wang X, Yu X, Liu C, Cheng H. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma. BMC Gastroenterology 2023, 23: 113. PMID: 37024802, PMCID: PMC10080823, DOI: 10.1186/s12876-023-02748-w.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCD8-Positive T-LymphocytesEndothelial CellsGene Expression Regulation, NeoplasticHumansPancreatic NeoplasmsPrognosisTumor MicroenvironmentConceptsTumor-infiltrating immune cellsExpression of OX40Risk score modelImmune cellsIdentified OX40Immune checkpointsOverall survivalScoring systemRisk scoreClinical specimensExpression of immune checkpoint genesCD8+ T cellsImmune checkpoint gene expressionSomatic mutationsProtein expressionHigh-risk score groupImmunogenic cell deathCheckpoint gene expressionImmune checkpoint expressionImmune checkpoint genesImmune cell infiltrationNaive B cellsCox regression analysisAssociated with increased survival ratesRisk scoring system
2020
Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma
Gong Y, Fan Z, Luo G, Huang Q, Qian Y, Cheng H, Jin K, Ni Q, Yu X, Liu C. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma. Pancreatology 2020, 20: 716-721. PMID: 32249060, DOI: 10.1016/j.pan.2020.02.016.Peer-Reviewed Original ResearchConceptsHistory of APPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinoma patientsLog-rank testAcute pancreatitisSurgical resectionDuctal adenocarcinomaPoor survivalHazard ratioHistory of acute pancreatitisDiagnosis of pancreatic ductal adenocarcinomaAssociated with poor survivalIndependent survival predictorMultivariable-adjusted hazard ratiosKaplan-Meier methodRetrospective cohort studyCox proportional hazards modelsProportional hazards modelOverall survivalRemote historyClinical characteristicsCohort studyMultivariate analysisRisk factorsKras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients
Cheng H, Luo G, Jin K, Fan Z, Huang Q, Gong Y, Xu J, Yu X, Liu C. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. Cancer Medicine 2020, 9: 2153-2159. PMID: 32017404, PMCID: PMC7064028, DOI: 10.1002/cam4.2895.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCD4 Lymphocyte CountCirculating Tumor DNADNA Mutational AnalysisFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedMutationNeoplasm StagingPancreatic NeoplasmsPolymerase Chain ReactionPrognosisProto-Oncogene Proteins p21(ras)Retrospective StudiesT-Lymphocytes, RegulatoryTime FactorsConceptsCell-free circulating tumor DNAAdvanced pancreatic cancer patientsPancreatic cancer patientsCirculating regulatory T cellsCirculating T-cell subsetsCA19-9 levelsRegulatory T cellsKRAS mutation statusT cell subsetsTumor-node-metastasisCancer patientsMutation statusTumor DNAKRAS mutationsT cellsAssociated with extremely poor survivalRegulatory T cell levelsAdvanced pancreatic cancerLevels of TregsProportion of TregsAbnormal immune statusCirculating tumor DNAT cell levelsPredicted worse prognosisTumor-node-metastasis stageResected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy
Liu C, Cheng H, Jin K, Fan Z, Gong Y, Qian Y, Deng S, Huang Q, Ni Q, Yu X, Luo G. Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. Cancer Control 2020, 27: 1073274820915947. PMID: 32268796, PMCID: PMC7153189, DOI: 10.1177/1073274820915947.Peer-Reviewed Original ResearchMeSH KeywordsChemotherapy, AdjuvantDeoxycytidineDrug Resistance, NeoplasmFemaleGemcitabineHumansLymph NodesLymphatic MetastasisMaleMiddle AgedPancreatic NeoplasmsConceptsGemcitabine-based adjuvant chemotherapyResectable pancreatic cancerPancreatic cancerAdjuvant chemotherapyN2 node involvementNode involvementCurative resection of pancreatic adenocarcinomaResection of pancreatic adenocarcinomaGemcitabine-based regimenGemcitabine-based treatmentNode-positive subgroupEfficacy of gemcitabineGemcitabine-based chemotherapyN2 tumorsAdjuvant regimenNodal involvementNodal statusNode-negativeCurative resectionPancreatic adenocarcinomaSubgroup patientsLymphatic metastasisChemotherapyPatientsCancer
2018
Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma
Liu C, Cheng H, Jin K, Guo M, Lu Y, Wang Z, Yang C, Long J, Ni Q, Yu X, Luo G. Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma. Pancreas 2018, 47: 742-747. PMID: 29851752, DOI: 10.1097/mpa.0000000000001073.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerAmerican Joint Committee on Cancer stageTumor resectionPancreatic cancerEighth editionAmerican Joint Committee on Cancer eighth editionAmerican Joint Committee on Cancer seventh editionStage classificationLymph node involvementEnd Results registrySeventh editionPrognosis to patientsNode involvementTumor diameterPositive nodesInstitutional seriesPancreatic adenocarcinomaCancer stageStage distributionSurvival curvesPatientsSurvival analysisTumorStatistical differenceCancer
2017
The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system
Yang C, Cheng H, Luo G, Lu Y, Guo M, Jin K, Wang Z, Yu X, Liu C. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system. European Journal Of Surgical Oncology 2017, 43: 2112-2118. PMID: 28802662, DOI: 10.1016/j.ejso.2017.07.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCA-125 AntigenCarcinoma, Pancreatic DuctalCD4 Lymphocyte CountCD8-Positive T-LymphocytesFemaleFlow CytometryHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPancreatic NeoplasmsPredictive Value of TestsPrognosisRetrospective StudiesSurvival RateTumor BurdenConceptsCD4/CD8 ratioNew scoring systemAdvanced pancreatic cancerCD8 ratioPrognosis of patientsCA125 levelsPancreatic cancerScoring systemPrognostic valueHigher CD4/CD8 ratioMultivariate analysisAdvanced pancreatic cancer patientsComplete clinical dataHigher CA125 levelsKaplan-Meier methodIndependent prognostic factorPancreatic cancer patientsLog-rank testTumor immune responseCox hazard modelPrognostic factorsCancer patientsMetastasis statusClinical dataImmune response
2016
Energy sources identify metabolic phenotypes in pancreatic cancer
Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu W, Liu J, Xiang J, Liang D, Hu Q, Liu L, Liu C, Luo G, Ni Q, Xu J, Yu X. Energy sources identify metabolic phenotypes in pancreatic cancer. Acta Biochimica Et Biophysica Sinica 2016, 48: 969-979. PMID: 27649892, DOI: 10.1093/abbs/gmw097.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaWarburg phenotypeMetabolic phenotypeInducing different metabolic phenotypesCancer metabolic reprogrammingPancreatic ductal adenocarcinoma treatmentHallmarks of cancerStratified pancreatic ductal adenocarcinomaIndividual metabolic phenotypeMetabolic reprogrammingMetabolic pathwaysMetabolic typeDuctal adenocarcinomaMalignant tumorsHeterogeneous diseasePhenotypeTherapeutic approachesEnergy metabolismMetabolic featuresMetabolic diseasesMetabolic inhibitorsNutritional substratesMetabolite detectionDiseaseGlutaminolysisOptimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping
Luo G, Guo M, Jin K, Liu Z, Liu C, Cheng H, Lu Y, Long J, Liu L, Xu J, Ni Q, Yu X. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Pancreatology 2016, 16: 1057-1062. PMID: 27692554, DOI: 10.1016/j.pan.2016.09.013.Peer-Reviewed Original ResearchConceptsDetect pancreatic cancerCut-off valueSensitivity of CA19-9CA19-9Pancreatic cancerEffectiveness of CA19-9Secretor genotypeStaging of pancreatic cancerII pancreatic cancerDetection of stage INegative predictive valueCohort of subjectsCA19Carbohydrate antigenStage IPredictive valueSanger sequencingCancerSecretor statusSecretorEarly detectorGenotypic backgroundGroupThe Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer
Guo M, Luo G, Liu C, Cheng H, Lu Y, Jin K, Liu Z, Long J, Liu L, Xu J, Huang D, Ni Q, Yu X. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. International Journal Of Molecular Sciences 2016, 17: 1090. PMID: 27399694, PMCID: PMC4964466, DOI: 10.3390/ijms17071090.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntigens, Tumor-Associated, CarbohydrateCarcinoma, Pancreatic DuctalChemotherapy, AdjuvantDisease-Free SurvivalErbB ReceptorsFemaleHumansImmunohistochemistryKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedMultivariate AnalysisPancreatic NeoplasmsPredictive Value of TestsPrognosisProportional Hazards ModelsRetrospective StudiesConceptsAdjuvant chemotherapyPostoperative survivalEGFR statusOverall survivalSurvival benefitEGFR expressionPancreatic cancerProlonged median overall survivalResected pancreatic cancer patientsAssociated with improved survivalSurgically resected pancreatic cancerMedian overall survivalResectable pancreatic cancerSignificant survival benefitEpidermal growth factor receptorKaplan-Meier analysisPancreatic cancer patientsPancreatic cancer treatmentStudies of EGFRGrowth factor receptorResectable PDACAdjuvant therapyPrognostic significanceImproved survivalExpression subgroupsCritical role of oncogenic KRAS in pancreatic cancer (Review)
LIU J, JI S, LIANG C, QIN Y, JIN K, LIANG D, XU W, SHI S, ZHANG B, LIU L, LIU C, XU J, NI Q, YU X. Critical role of oncogenic KRAS in pancreatic cancer (Review). Molecular Medicine Reports 2016, 13: 4943-4949. PMID: 27121414, DOI: 10.3892/mmr.2016.5196.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPancreatic cancerGenetically engineered mouse modelsPancreatic intraepithelial neoplasiaDevelopment of pancreatic ductal adenocarcinomaFormation of pancreatic intraepithelial neoplasiaProgression of pancreatic ductal adenocarcinomaIntraepithelial neoplasiaHigher mortality rateMutated KRASDuctal adenocarcinomaMouse modelHuman malignanciesKRASKRAS signalingPharmacological inhibitionOncogenic KRASPharmacological targetsMortality rateCancerTargeting KRASMolecular mechanismsProgressionWhich patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer?
Liu C, Lu Y, Luo G, Cheng H, Guo M, Liu Z, Xu J, Long J, Liu L, Fu D, Ni Q, Li M, Yu X. Which patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer? Oncotarget 2016, 7: 29177-29186. PMID: 27081079, PMCID: PMC5045387, DOI: 10.18632/oncotarget.8690.Peer-Reviewed Original ResearchConceptsPancreatic head cancerResectable pancreatic head cancerLymph node ratioHead cancerLymph nodesTumor locationPara-aortic lymph node dissectionPara-aortic lymph node metastasisPara-aortic lymph nodesCurative surgical resectionLymph node dissectionIndependent prognostic factorLymph node metastasisPoor surgical outcomesDuctal adenocarcinoma patientsPoor prognostic markerPreoperative serum CA125Curative pancreaticoduodenectomyNode dissectionPancreatic headRadical surgerySurgical resectionNode metastasisPrognostic factorsSuch patientsALDOA functions as an oncogene in the highly metastatic pancreatic cancer
Ji S, Zhang B, Liu J, Qin Y, Liang C, Shi S, Jin K, Liang D, Xu W, Xu H, Wang W, Wu C, Liu L, Liu C, Xu J, Ni Q, Yu X. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Cancer Letters 2016, 374: 127-135. PMID: 26854714, DOI: 10.1016/j.canlet.2016.01.054.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkers, TumorCadherinsCarcinoma, Pancreatic DuctalCell Line, TumorFructose-Bisphosphate AldolaseGlycolysisHeterograftsHigh-Throughput Screening AssaysHumansMaleMiceMice, NudeNeoplasm InvasivenessNeoplasm MetastasisOncogenesPancreatic NeoplasmsReactive Oxygen SpeciesSignal TransductionConceptsHigh-throughput screening analysisAldolase APancreatic cancerRegulation of c-MycTGF-bE-cadherinAnalyzed gene expression signaturesRegulation of glycolysisResistant to conventional treatmentPancreatic cancer cell line PANC-1Cancer metabolic changesPrognosis of pancreatic cancerTransforming growth factor-bSubgroup of patientsCell line PANC-1Metastasis of pancreatic cancer cellsPoor prognosis of pancreatic cancerExpression regulationGene expression signaturesPancreatic cancer tissue samplesPancreatic cancer cellsGlycolytic genesGrowth factor BE-cadherin expressionCancer tissue samples
2015
Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus statement by the Chinese Study Group for Pancreatic Cancer (CSPAC)
LIU C, CHEN R, CHEN Y, FU D, HONG D, HAO J, LIU D, LI J, LI S, LI Y, MAI G, MOU Y, NI Q, PENG L, QIAN H, QIN R, SUN B, SHAO C, SUN Y, TIAN B, WANG J, WANG W, WANG W, ZHAO G, YU X. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus statement by the Chinese Study Group for Pancreatic Cancer (CSPAC). International Journal Of Oncology 2015, 47: 1512-1516. PMID: 26314752, DOI: 10.3892/ijo.2015.3128.Peer-Reviewed Original ResearchConceptsPara-aortic lymph nodesPancreatic head cancerHead cancerCurative surgeryChinese Study GroupLymph nodesStandard lymphadenectomyPancreatic cancerResectable pancreatic head cancerStudy groupCases of pancreatic head cancerHigh-volume centersPancreatic cancer patientsResection statusTumor burdenPrimary tumorResected casesNode stationsPoor prognosisCancer casesCancer patientsDorsal pancreasConsensus statementSurgeryCancerPapillary-like main pancreatic duct invaginated pancreaticojejunostomy versus duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: A prospective randomized trial
Xu J, Zhang B, Shi S, Qin Y, Ji S, Xu W, Liu J, Liu L, Liu C, Long J, Ni Q, Yu X. Papillary-like main pancreatic duct invaginated pancreaticojejunostomy versus duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: A prospective randomized trial. Surgery 2015, 158: 1211-1218. PMID: 26036878, DOI: 10.1016/j.surg.2015.04.020.Peer-Reviewed Original ResearchConceptsNondilated main pancreatic ductPostoperative pancreatic fistulaPostoperative pancreatic fistula rateDuct-to-mucosa pancreaticojejunostomyDuct-to-mucosa groupMain pancreatic ductPancreatic ductIncidence of grade B/C postoperative pancreatic fistulasGrade B/C postoperative pancreatic fistulaB/C postoperative pancreatic fistulaDilated main pancreatic ductHigher body mass indexSignificant risk factorsBody mass indexLonger operative timePOPF rateInvagination pancreaticojejunostomyPancreatic fistulaPancreatic anastomosisRetrospective studyPancreaticojejunostomyMass indexMultivariate analysisOperative timePancreaticoduodenectomyLymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer
Liu Z, Luo G, Guo M, Jin K, Xiao Z, Liu L, Liu C, Xu J, Ni Q, Long J, Yu X. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Pancreatology 2015, 15: 253-258. PMID: 25921232, DOI: 10.1016/j.pan.2015.03.012.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantDeoxycytidineFemaleHumansLymph NodesLymphatic MetastasisMaleMiddle AgedPancreatectomyPancreatic NeoplasmsRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsAdjuvant chemoradiotherapyLymph node statusNode statusPancreatic cancerPancreatic adenocarcinomaDifferent lymph node statusCurative R0 resectionEffect of chemoradiotherapyImproved median OSLN-negative diseaseLN-positive diseaseRole of lymphOverall median survivalMedian OSAdjuvant therapyR0 resectionMedian survivalPositive diseaseNegative diseaseChemoradiotherapyPatientsMultivariate analysisDiseaseLymphAdenocarcinomaMetabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer
Shi S, Ji S, Qin Y, Xu J, Zhang B, Xu W, Liu J, Long J, Liu C, Liu L, Ni Q, Yu X. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Cancer Letters 2015, 360: 227-233. PMID: 25687883, DOI: 10.1016/j.canlet.2015.02.014.Peer-Reviewed Original ResearchConceptsMetabolic tumor burdenMetabolic tumor volumeSerum tumor markersTumor burdenTumor markersPancreatic cancerAbnormal expressions of TP53Abnormal expressionMonitoring treatment responsePancreatic cancer patientsProgression of pancreatic cancerExpression of TP53Tumor volumeCA19-9SMAD4/DPC4 geneTreatment responseCancer patientsDisease progressionPET/CTPredictive significanceSurvival rateLethal diseasePatientsCancerSerum
2014
Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy
Luo G, Guo M, Liu Z, Xiao Z, Jin K, Long J, Liu L, Liu C, Xu J, Ni Q, Yu X. Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy. Annals Of Surgical Oncology 2014, 22: 670-676. PMID: 25155401, DOI: 10.1245/s10434-014-4021-y.Peer-Reviewed Original ResearchConceptsNeutrophil-to-lymphocyte ratioBaseline neutrophil-to-lymphocyte ratioAdvanced pancreatic cancerNLR changeOverall survivalPancreatic cancerPrognostic roleMultivariate analysisPredictor of overall survivalSerum CA19-9 levelsPredictor of poor survivalAdvanced pancreatic adenocarcinomaCA19-9 levelsSerum albumin levelCox proportional hazards modelsProportional hazards modelPostchemotherapy changesClinicopathological predictorsDistant metastasisPrognostic factorsPancreatic adenocarcinomaClinicopathological characteristicsAlbumin levelsPoor survivalPredicting survival18F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors
Luo G, Liu Z, Guo M, Jin K, Xiao Z, Liu L, Xu J, Zhang B, Liu C, Huang D, Hu S, Ni Q, Long J, Yu X. 18F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. International Journal Of Oncology 2014, 45: 1531-1536. PMID: 25096059, DOI: 10.3892/ijo.2014.2570.Peer-Reviewed Original ResearchConceptsNon-functioning pancreatic neuroendocrine tumorsPancreatic neuroendocrine tumorsPET/CTNeuroendocrine tumorsNon-functioning endocrine pancreatic tumorsPET/CT scansDistant metastatic lesionsShanghai Cancer CenterEndocrine pancreatic tumorsClinical characteristicsMetastatic lesionsTumor sizeCancer CenterTNM stagePancreatic tumorsLarge cohortCT scanClinical valueAdvanced stageSignificant associationTumorsPatientsCTCohortLesions“Tissue is the Issue”: Circulating Tumor Cells in Pancreatic Cancer
George T, Ogunwobi O, Sheng W, Fan Z, Liu C. “Tissue is the Issue”: Circulating Tumor Cells in Pancreatic Cancer. Journal Of Gastrointestinal Cancer 2014, 45: 222-225. PMID: 25012516, PMCID: PMC4440834, DOI: 10.1007/s12029-014-9638-3.Peer-Reviewed Original ResearchThe UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma
Liu C, Karam R, Zhou Y, Su F, Ji Y, Li G, Xu G, Lu L, Wang C, Song M, Zhu J, Wang Y, Zhao Y, Foo W, Zuo M, Valasek M, Javle M, Wilkinson M, Lu Y. The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. Nature Medicine 2014, 20: 596-598. PMID: 24859531, PMCID: PMC4048332, DOI: 10.1038/nm.3548.Peer-Reviewed Original ResearchMeSH KeywordsAlternative SplicingBase SequenceCarcinoma, AdenosquamousGene ComponentsHEK293 CellsHumansImmunohistochemistryIn Situ Nick-End LabelingMolecular Sequence DataMutagenesisMutationNonsense Mediated mRNA DecayPancreatic NeoplasmsReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA HelicasesSequence Analysis, DNATrans-Activators